YouthBio secures FDA INTERACT feedback for YB002 Alzheimer’s gene therapy

YouthBio Therapeutics has received positive feedback from the U.S. Food and Drug Administration (FDA) following an INTERACT meeting regarding its investigational gene therapy, YB002, aimed at treating Alzheimer’s disease. The FDA’s response indicates that existing preclinical data support the bioactivity of YB002 and the company’s proposed plans for a first-in-human trial. YB002 is a gene […] The post YouthBio secures FDA INTERACT feedback for YB002 Alzheimer’s gene therapy appeared first on Longevity.Technology.